SPARC and cleidocranial dysplasia 1: Hence, the observed increased levels of RUNX2 protein in os-fibroblasts of both CCD patients might be the consequence of compensation mechanisms for the reduced expression of downstream osteogenic genes, such as SPARC, or of the accumulation of dysfunctional RUNX2.